Madrigal Pharmaceuticals, Inc.
MDGLHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeMadrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company carries a $10.03B market cap, placing it firmly in the large-cap category. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Market Cap
$10.03B
Beta
-1.05
P/E (TTM)
—
P/E (Fwd)
45.12
EPS (TTM)
$-12.85
EPS (Fwd)
$9.63
ROE
-53.3%
ROA
-17.8%
Cash
$838.8M
Total Debt
$347.8M
Free CF
-$80.5M
52W Change
3.0%
Annual Financials
Cash vs Debt
Where MDGL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MDGL finished 12.83% below its 150-day moving average ($512.91) and 11.37% below its 200-day moving average ($504.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDGL overbought or oversold?
At the October 20, 2026 close, MDGL's RSI(14) was 12.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $838.8M in cash comfortably exceeding the $347.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$80.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -53.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -1.05 suggests MDGL is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MDGL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.